Testing Method Sample Clauses

Testing Method. 1. The selected testing agency may conduct the standard 5 or 10-part drug panel test for the presence of the following categories of drugs and all substances produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: Amphetamines Methadone Barbiturate Methaqualone Benzodiazepine Opiates Cannabinoids Phencyclidines Cocaine Proxyohene 2. The selected testing agency shall set sensitivity cut off levels in accordance with the standard drug levels currently used by laboratories for screening and confirming test results, as follows: Initial and First Confirmation Test (ng/ml) Amphetamines1,000 Barbiturate 200 Benzodiazepine 300 Cannabinoids 50 Cocaine metabolites 300 Methadone 300 Methaqualone 300 Opiates metabolites *2000 Phencyclidine 25 Propoxyophene 300 * 25 ng/ml if immunoassay specific for free morphine. Gas Chromatography / Mass Spectrometry (ng/ml) Amphetamines: Amphetamine 500 Methamphetamine 500 Barbiturate 200 Benzodiazepine 300 Cannabinoids (1) 15 Cocaine metabolites (2) 150 Methadone 200 Methaqualone 200 Opiates: Codeine 2000 Morphine 2000 Phencyclidine 25 Propoxyophene 300 (1) Delta-9-tetrahhydrocannainol-9-carboxylic

Testing Method. 14 For Ethernet applications, it is suggested that the CFP module be tested per the optical test methods 15 outlined in IEEE 802.3 clauses 86, 87 and 88.

Testing Method. 1. No employee subject to drug testing shall be considered testing positive unless: A urinalysis drug test utilizing a reliable scientific methodology was given and produced a positive result Such positive test result was confirmed by a second urinalysis drug test, which was separate and independent from the initial, utilizing a reliable scientific methodology Such positive test result was confirmed by a third urinalysis drug test which was separate and independent from the initial test, utilizing a gas chromatography and mass spectrometry methodology The affected employee fails to substantiate a medical or legal reason for the positive test result to the Medical Review Officer. 2. The selected testing agency shall test for the presence of the following category of drugs and all substances produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: 1. Cannabinoids 6. Barbituates 2. Cocaine 7. Benzodiazepine 3. Opiates 8. Methadone

Testing Method. All test samples shall be taken by a medically trained practitioner designated by the ship-owner, excluding breathalyser tests. The practitioner must follow common, good practices of their respective field, with their sampling practic- es, transport of samples, analysis, evaluation, reporting of results and confi- dentiality.

Testing Method. For the purpose of this Section, when calculating the ADP for the group of Nonhighly Compensated Employees who are Participants, the current year testing method shall be used. Once the current year testing method has been elected, then the Employer may elect to use the prior year testing method for a Plan Year only if the Plan has used the current year testing method for each of the preceding 5 Plan Years (or if lesser, the number of Plan Years that the Plan has been in existence) or if, as a result of a merger or acquisition described in Code Section 410(b)(6)(C)(i), the Employer maintains both a plan using prior year testing method and a plan using current year testing method and the change is made within the transition period described in Code Section 410(b)(6)(C)(ii).

Testing Method. METHOD EXPECTED RESULT ------ --------------- 7.1 Visual Material check Conforms to Certificate of Analysis (COA) description. Label text check Matches current approved text (See Master Label Log). Kit check Kit is clean and free of debris, spilled reagents, etc. Expiration date Conforms to Manufacturer's expiration date from (COA). Lot Number Conforms to Manufacturer's Lot Number from (COA). 7.2 Performance Testing (vs. QC Reference Chart) (See page 2 for procedure) a. Should be inside result window. b. Lines should not touch either edge of window. c. There should be a minimum of 1mm spacing between lines. 8. SPECIFICATIONS: N/A

Testing Method. METHOD EXPECTED RESULT ------ --------------- 7.1 Visual Material check Conforms to Certificate of Analysis (COA) description. Label text check Matches current approved text (See Master Label Log). Kit check Kit is clean and free of debris, spilled reagents, etc. Expiration date Conforms to Manufacturer's expiration date from (COA). Lot Number Conforms to Manufacturer's Lot Number from (COA). 7.2 Performance Testing (vs. QC Reference Chart) (See page 2 for procedure) Negate Control Negative is clean 500mlp/mL LH < + - - 25mlp/mL hCG > - 1.5 + - 500mlp/mL hCG > 2 + - Control line Clearly visible red line a. Should be inside result window. b. Lines should have no major breaks in line form. 8. PURCHASE SPECIFICATION: N/A ACCEAVA HCG 20 TEST KIT DOC. NO. RMACCHCG.00 (PART # ACCHCG) PAGE 2 OF 3 ================================================================================ 2. PERFORMANCE TESTING PROCEDURE (7.2) TEST MATERIALS LOT # Test Sticks ------------------------------ Negative Control ------------------------------ 500mlp/mL LH ------------------------------ 25mlp/mL hCG ------------------------------ 500mlp/mL hCG ------------------------------ TEST PROCEDURE Test 3 sticks for each of the control samples. Remove sufficient solution into a tube to dip the entire tip of the entire absorbent tip of the stick into the test solution for 3 seconds. Place the stick on a clean, fiat, dry disposable surface. Other Inspections: Inspect Control Line intensity during QC testing. The Control Line should be a visible red line. Inspect Test and Control Line location during QC testing. The Test and Control Lines should be inside the result window with no major break in the line form. Record the results on the QC Testing Data Sheet. The lot is deemed acceptable when all test results recorded on the sheets are within the specifications listed. If any non-conforming result occurred, the lot should be withheld for further review and disposition. 21 ACCEAVA HCG 20 TEST KIT DOC. NO. RMACCHCG.00 (PART # ACCHCG) PAGE 3 OF 3 ================================================================================ INSPECTION RECORD: Manufacturer: ______________________ Date Received _____________________ Manufacturer Lot #: ________________ BioStar Lot #: ____________________ Manufacturer Exp. Date: ____________ BioStar Exp. Date: ________________ P.O. #: ____________________________ Quantity Received: ________________ =====================================================================...

Testing Method. The ACP Test will be determined each Plan Year by either Current Year Testing or Prior Year Testing (as described in paragraph (b) below) as follows: Current Year Testing is used for the 1997 Plan Year; Current Year Testing is used for the 1998 Plan Year; Current Year Testing is used for the 1999 Plan Year; Current Year Testing is used for the 2000 Plan Year; and Current Year Testing is used for the 2001 Plan Year; and Current Year Testing is used for the 2002 Plan Year and for each Plan Year thereafter until otherwise elected by the Employer by means of a Plan amendment.

Testing Method. The ADP Test will be determined each Plan Year by either Current Year Testing or Prior Year Testing (as described in paragraph (b) below) as follows: Current Year Testing is used for the 1997 Plan Year; Current Year Testing is used for the 1998 Plan Year; Current Year Testing is used for the 1999 Plan Year; Current Year Testing is used for the 2000 Plan Year; Current Year Testing is used for the 2001 Plan Year; and Current Year Testing is used for the 2002 Plan Year and for each Plan Year thereafter until otherwise elected by the Employer by means of a Plan amendment.

Testing Method. The ADP and/or ACP testing shall be applied using: (Select only one.) PRIOR YEAR TESTING METHOD (referred to in Sections 3.1(e)(1) and 3.2(b)(1)).